We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 11, 2021

Adjuvant Icotinib Improves DFS vs Chemotherapy in Stage IIV–IIIA EGFR-Mutant NSCLC

The Lancet Respiratory Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Icotinib Versus Chemotherapy as Adjuvant Treatment for Stage II-IIIA EGFR-Mutant Non-Small-Cell Lung Cancer (EVIDENCE): A Randomised, Open-Label, Phase 3 Trial
Lancet Respir Med 2021 Jul 16;[EPub Ahead of Print], J He, C Su, W Liang, S Xu, L Wu, X Fu, X Zhang, D Ge, Q Chen, W Mao, L Xu, C Chen, B Hu, G Shao, J Hu, J Zhao, X Liu, Z Liu, Z Wang, Z Xiao, T Gong, W Lin, X Li, F Ye, Y Liu, H Ma, Y Huang, J Zhou, Z Wang, J Fu, L Ding, L Mao, C Zhou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading